Cagrilintide Results Timeline
What the standard Cagrilintide research protocol looks like phase by phase, over a typical 16+ weeks cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Quick Facts
FREQUENCYOnce weekly
CYCLE LENGTH16+ weeks
DOSE RANGE0.6–4.5 mg weekly
ROUTESubcutaneous injection
Phase-by-Phase Timeline
Loading / Titration
Weeks 1–2
Target dose: 0.6 mg
Escalation
Weeks 3–4
Target dose: 1.2 mg
Escalation
Weeks 5–6
Target dose: 2.4 mg
Maintenance
Weeks 7+
Target dose: 4.5 mg
Reported in Research
- ✓Escalation every 2 weeks is more aggressive than semaglutide — monitor GI tolerance.
- ✓16+ weeks; REDEFINE trial data extends to 68 weeks.
- ✓Escalation every 2 weeks.
This timeline reflects the structure of the standard Cagrilintide research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.